Overview

All information and news about Medincell stock (Euronext Paris: MEDCL)

Medincell share price

28.38€

0.64 / 2.31%

2026-01-22 09:06 (Paris)

Data provided by Euronext, in real time.

See stock quote, chart & historical on Euronext.com

Listed on

Euronext Paris /
B Compartment

ISIN code / Ticker

FR0004065605 /
MEDCL

Number of shares

33,098,886
(September 30, 2025)

Liquidity Provider

Rothschild Martin Maurel

Analyst coverage

Medincell is followed by the analysts listed. Please note that any opinions, estimates, or forecasts regarding Medincell’s performance made by these analysts are theirs alone and do not represent opinions, forecasts, or predictions of Medincell or its management. Medincell does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions, or recommendations.

Company

Analyst

Contact

Evercore

Michael DiFiore

Truist Securities

Les Sulewski

H.C. Wainwright & Co.

Raghuram Selvaraju

Jefferies

Shan Hama

Stifel

Oscar Haffen Lamm

ODDO BHF

Martial Descoutures

Kepler Chevreux

Nicolas Pauillac

Portzamparc

Mohamed Kaabouni

TP ICAP

Jean-Pierre Tabart

Documentation

December 2025

Corporate presentation

2025

CSR report

Latest news

Half-year liquidity contract statement
January 20, 2026

Half-year liquidity contract statement

Publication of the 2026 financial calendar
January 12, 2026

Publication of the 2026 financial calendar

[Replay] Webcast – HY Results – Dec. 9, 2025
December 10, 2025

[Replay] Webcast – HY Results – Dec. 9, 2025

Medincell Publishes its Consolidated Half-Year Financial Results (April 1st , 2025 – September 30, 2025)
December 9, 2025

Medincell Publishes its Consolidated Half-Year Financial Results (April 1st , 2025 – September 30, 2025)

Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults
December 9, 2025

Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults

Investors contacts

Medincell

David Heuzé

Head of Corporate and Financial Communications, and ESG

Medincell

Grace Kim

Head of US Financial Strategy & IR

Investor relations

Louis-Victor Delouvrier
& Alban Dufumier

Newcap

Media

Nicolas Merigeau

Newcap